|
Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II Clinical Trials Info presented on Clinical Trials Search isn't intended to be a substitute for certified medical advice, calls or professional assistance using a genuine dr.. We aren't physicians. Always confer with your dr. on Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II Clinical research trials and Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II medical trials happen in hundreds of localities throughout the U.S.A.. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials typically measure the effectualness of new does drugs. The intent of the studies / undertakings is to answer particular human health questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to find cures for all kinds of circumstances, like Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II. Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II Clinical Trials and other clinical trials permit volunteers to acquire healthcare treatment options before they are available to the general public. Some times the subjects acquire professional assistance for free, and sometimes they are paid for their time. Sometimes there is a cost for a Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II clinical trial. Participants frequently obtain the most expert healthcare available for their Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II condition. Dangers are a reality, nevertheless, and can include more or frequent doctor calls, health risks (potentially life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with strict guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "P" Clinical Trials Conditions > Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II  Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II
Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II
For Condition: Anemia, Sickle Cell,Chlamydia Infections,Blood Disease,Cerebrovascular Accident
Status: No longer recruiting
Sponsor(s): National Heart, Lung, and Blood Institute (NHLBI) ,
Synopsis: To establish a link among Chlamydia infection, sickle cell anemia, and stroke risk.
Details: BACKGROUND: Infection with Chlamydia pneumoniae (C. pneumoniae) is associated with an increased risk of cerebrovascular disease in the general population. Children with sickle cell anemia (SCA) are 200 times more likely to have cerebrovascular disease than normal children and are known to have an altered immune response to many infectious pathogens. C. pneumoniae is the leading infectious cause of acute chest syndrome which, interestingly, is a well- established risk factor for stroke in children with SCA. Preliminary data indicates that SCA patients with magnetic resonance imaging (MRI)-documented cerebral infarction are 12 times more likely to have C. pneumoniae infection than SCA patients with normal MRI scans. The investigators hypothesize that SCA patients have an abnormal immune response to C. pneumoniae that results in persistent infection which, in turn, triggers the development of cerebrovascular disease. Sickle cell anemia patients with an elevated velocity on transcranial doppler ultrasound (TCD) are known to be at high risk to develop stroke and an elevated TCD likely reflects underlying vascular disease. In addition, the Stroke Prevention in Sickle Cell Anemia Trial (STOP) demonstrated that almost 40 percent of children with an elevated TCD have evidence of cerebral infarction on MRI. Children with abnormal TCDs are, therefore, an appropriate population to investigate an association between cerebrovascular disease and C. pneumoniae infection. The study is in response to an initiative on Ancillary Studies in Heart, Lung, and Blood Disease Trials released in June, 2000. DESIGN NARRATIVE: The study is ancillary to the STOP II clinical trial. The intent is: 1) To determine if C. pneumoniae infection is associated with cerebral infarction in children with SCA; 2) To characterize the immunological response to C. pneumoniae infection in patients with SCA. Establishing a link between C.pneumoniae infection and cerebral infarction will open the door to novel, less toxic approaches to the treatment and prevention of stroke in SCA, including antibiotics and vaccines.
Eligibility:
Study Type: Observational, Defined Population, Retrospective Study
Minimum Age/Maximum Age: /
Genders: Both
Protocol Entry Criteria: No eligibility criteria
Total Enrollment:
Location and Contact Information:
Overall Study Official:
LoriStyles, , Children's Hospital, Oakland
Additional Information:
Study ID Numbers: 1167;
Study Start Date: September 2001
Record last reviewed: March 2004
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00037388
Other Chlamydia Infections Studies:
1. Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II
2. Prevention of Cerebral Infarction in Sickle Cell Anemia - Comprehensive Sickle Cell Center
3. Sibling Donor Cord Blood Banking and Transplantation
4. Pediatric Hydroxyurea in Sickle Cell Anemia (BABY HUG)
5. Induction of Stable Chimerism for Sickle Cell Anemia
Related Studies:
Other Chlamydia Infections Clinical Trials
Other Clinical Trials
Other Clinical Trials
Pediatrics:Chlamydia, Sickle Cell Anemia and Stroke Risk - Ancillary to STOP II
|
|
|
|
|
|
|
|
